{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000722","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.506288+00:00","generated_at":"2026-06-15T21:16:55.707931+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aldeyra Q1 net loss $15.6M; PDUFA dates set; clinical readouts in Q2 2023","bullets":["Net loss $15.6M ($0.27 loss per share) vs $16.8M ($0.29) in Q1 2022.","Cash and equivalents $165.0M; projected runway into H2 2024.","PDUFA dates: ADX-2191 (June 21, 2023) for vitreoretinal lymphoma; reproxalap (Nov 23, 2023) for dry eye.","Top-line Q2 2023: Phase 2 ADX-2191 (retinitis pigmentosa), Phase 2 ADX-629 (chronic cough), Phase 3 INVIGORATE-2 (allergic conjunctivitis).","Aldeyra will discontinue quarterly earnings conference calls, citing shift to clinical/regulatory updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000722","json":"https://secwatch.observer/filing/0001157523-23-000722.json","markdown":"https://secwatch.observer/filing/0001157523-23-000722.md","text":"https://secwatch.observer/filing/0001157523-23-000722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/0001157523-23-000722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/a53393376.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:16:55.707931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b375a2dbf25cd7db4980971a7a69564b6682645d","claim":"Aldeyra Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 4, 2023, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) issued a press release (the “Press Release”) regarding its financial results for the quarter ended March 31, 2023 and recent corporate highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/0001157523-23-000722-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}